Omzo vs Mochi Health: Clinician-Guided Plans vs Live Video Visits
Omzo vs Mochi Health pits Omzo’s clinician-guided, compounded semaglutide program starting at $179 against Mochi Health’s live video doctor visits and membership-plus-medication pricing beginning from $99/month. Quick verdict: choose Omzo if you want clinician-reviewed, compounded semaglutide programs with clinician discretion; choose Mochi Health if you prefer live video visits and a membership model that can start as low as $99/month.
Explore Omzo clinician-guided plans
Head-to-head differences at a glance
This comparison focuses on the most distinctive supported differences between Omzo and Mochi Health: clinical model and visit type, pricing structure and starting costs, medication format and regulatory notices, availability and state coverage, and support and appointment access.
1. Clinical model and visit experience
Omzo: The Omzo platform connects you with licensed U.S. providers who review plans; clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make the final determination as to whether to prescribe medication. Omzo notes it is not a medical practice and that the assessment on its website does not create a doctor patient relationship. Clinician-guided plans are emphasized.
Mochi Health: Mochi distinguishes itself with live video visits bookable in about 5 minutes. Mochi positions its synchronous video visits as fundamentally different from the asynchronous text reviews used by many competitors, allowing a real-time conversation where a physician evaluates the case and answers questions during the consultation.
2. Pricing structure and starting costs
Omzo: Lists semaglutide starting at $179 and tirzepatide starting at $279. Pricing points are presented as starting at amounts and Omzo warns pricing, eligibility, pharmacy, state coverage and renewal terms may change.
Mochi Health: Uses a membership-plus-medication model with promotional offers. Mochi advertises compounded semaglutide from $99 and notes membership plus medication pricing starting as low as $99/month. New patients can get 50% off their first month with code BESTWLHALFOFF and a promotional first month rate such as $39 for certain offers; the site notes the $39 promotional rate applies to first month only for new customers and standard rate after that is $79 per month, with terms varying by state.
3. Medication types and regulatory notes
Omzo: Emphasizes a compounded medication program prepared by state licensed sterile compounding pharmacies. Omzo explicitly states compounded drugs are not FDA approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Omzo also notes providers may instead write prescriptions for branded FDA approved medications but Omzo does not sell or ship branded medications.
Mochi Health: Also offers compounded semaglutide and tirzepatide options and lists various compounded forms including a compounded semaglutide pill and compounded orforglipron. Mochi likewise includes the regulatory note that compounded medications are not FDA approved and are not reviewed by FDA for safety, effectiveness or quality.
4. Availability, states and support
Omzo: Clinical services operate through third party networks of U.S.-licensed clinicians and Omzo advises confirming eligibility, medication, total cost, renewal terms and state availability before enrollment. Omzo warns eligibility and state coverage may change.
Mochi Health: States it provides reliable GLP-1 prescription access in all 50 states and highlights 24/7 support plus ongoing appointment availability throughout the program. Mochi emphasizes members can continue care beyond the first month.
5. Ongoing care and appointment access
Omzo: Focuses on clinician-guided plans reviewed by licensed U.S. providers and highlights provider discretion on prescribing. The platform notes providers determine eligibility based on medical history and provider assessment.
Mochi Health: Emphasizes easy booking of live video visits in about 5 minutes, ongoing appointment availability, and 24/7 support as part of its offering. Mochi calls out that synchronous consultations allow direct question and answer during the visit.
Comparison table
| Criteria | Omzo | Mochi Health |
|---|---|---|
| Clinical model | Clinician guided, third party U.S. licensed clinicians review plans | Live video visits with a doctor bookable in about 5 minutes |
| Starting price | Semaglutide starting at $179 | Membership plus medication from $99/month; compounded semaglutide from $99 |
| Medication types | Compounded semaglutide and tirzepatide; prescriptions for branded meds possible | Compounded semaglutide, tirzepatide, oral options, and other compounded meds |
| Regulatory note | Compounded meds not FDA approved | Compounded meds not FDA approved |
| State coverage | Confirm state availability; may vary | Reliable prescription access in all 50 states |
| Support and access | Clinician-guided plans with provider discretion | 24/7 support and ongoing appointments |
How to choose between Omzo and Mochi Health
Both platforms focus on GLP-1 access and use clinician discretion when prescribing. The decisive elements are visit style, pricing structure, and regulatory framing of compounded meds. Mochi Health is centered on synchronous live video visits and a membership model with promotional first month pricing and nationwide prescription access. Omzo centers on clinician-guided, reviewed plans with compounded medication programs and starting pricing points listed for semaglutide and tirzepatide while advising confirmation of eligibility and state availability.
Choose Omzo if you prioritize clinician-guided plans reviewed by licensed U.S. providers, access to compounded semaglutide and tirzepatide with starting prices like semaglutide starting at $179, and a model where providers determine eligibility and prescribing. Choose Mochi Health if you want live video visits with a doctor in about 5 minutes, membership-plus-medication pricing from $99/month with promotional first month offers, and 24/7 support with nationwide prescription access.